Human C-Type Lectin Domain Family 9 Member A (CLEC9A) ELISA Kit

Product specifications

ELISA Kits

C-Type Lectin Domain Family 9 Member A (CLEC9A)

Human

Colorimetric

Quantitative

Sandwich

0.313 ng/ml - 20 ng/ml

< 0.188 ng/ml

Optimal dilutions/concentrations should be determined by the end user.

96 tests

Lyophilized

ELISA

Tissue homogenates, cell lysates and other biological fluids.

Shipped within 5-12 working days. The validity for this kit is 6 months.

Shipped at 4 °C. Upon receipt, store the kit according to the storage instruction in the kit's manual.

No

Q6UXN8

283420

612252

CD370,DNGR1,DNGR-1,

Elisa kits for CLEC9A

RUO

Validity: The validity for this kit is 6 months.
This product is for research use only.   The range and sensitivity is subject to change. Please contact us for the latest product information. For accurate results, sample concentrations must be diluted to mid-range of the kit. If you require a specific range, please contact us in advance or write your request in your order comments.   Please note that our ELISA and CLIA kits are optimised for detection of native samples, rather than recombinant proteins. We are unable to guarantee detection of recombinant proteins, as they may have different sequences or tertiary structures to the native protein.

Descripción

CLEC9A, also known as C-type lectin domain family 9 member A or DNGR-1 (Dendritic Cell Natural Killer Lectin Group Receptor 1), is an immune receptor primarily expressed on a subset of dendritic cells (DCs) and certain populations of macrophages. CLEC9A is part of the C-type lectin receptor (CLR) family, which is known for its role in recognizing carbohydrate structures on pathogens, triggering immune responses, and presenting antigens to T cells. However, CLEC9A is unique within this family for its specialized function in detecting necrotic cells and facilitating the cross-presentation of antigens from dead cells. This capability enables CLEC9A to bridge innate and adaptive immunity, playing a significant role in immune responses to infections, cancer, and tissue injury.The receptor's ability to recognize damaged cells, rather than simply pathogens, underscores its importance in contexts such as infection, cancer immunology, and autoimmunity. CLEC9A has therefore gained interest for its potential applications in vaccine development and immunotherapy. Its expression is mainly restricted to CD8+ DCs and their human equivalent, BDCA3+ DCs, which are specialized for cross-presentation, making CLEC9A a critical component in inducing CD8+ T cell responses.

Related Products

CLEC9A antibody

Functions as an endocytic receptor on a small subset of myeloid cells specialized for the uptake and processing of material from dead cells. Recognizes filamentous form of actin in association with particular actin-binding domains of cytoskeletal proteins, including spectrin, exposed when cell membranes are damaged, and mediate the cross-presentation of dead-cell associated antigens in a Syk-dependent manner.

Ver Producto

Recombinant Human CLEC9A

Ver Producto

C-Type Lectin Domain Family 9 Member A (CLEC9A) Antibody

CLEC9A is a group V C-type lectin-like receptor (CTLR) that functions as an activation receptor and is expressed on myeloid lineage cells (Huysamen et al., 2008 [PubMed 18408006]).

Ver Producto